Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: Paroxetine vs. bupropion

Psychiatry Research

Volumn 225, Issue 3, 2015, Pages 407-412

  Gorlyn, Marianne ^a,b   Keilp, John ^a,b   Burke, Ainsley ^a,b   Oquendo, Maria ^a,b   Mann, J John ^a,b   Grunebaum, Michael ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Antidepressant treatment; Cognition; Major depression; Suicide

Indexed keywords

AMFEBUTAMONE; PAROXETINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DSM-IV; FEMALE; HAMILTON DEPRESSION RATING SCALE; HIGH RISK PATIENT; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESPONSE; VERBAL MEMORY; WECHSLER INTELLIGENCE SCALE; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 84922764317     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.12.004     Document Type: Article

References (44)

1. Banaschewski T., Roessner V., Dittmann R.W., Santosh P.J., Rothenberger A. Non-stimulant medications in the treatment of ADHD. European Child and Adolescent Psychiatry 2004, 13:I102-I116.
2. Barrickman L.L., Perry P.J., Allen A.J., Kuperman S., Arndt S.V., Herrmann K.J., Schumacher E. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34:649-657.
3. Beck A.T., Kovacs M., Weissman A. Assessment of suicidal intention: the scale for suicide ideation. Journal of Consulting and Clinical Psychology 1979, 47:343-352.
4. Beck A.T., Steer R.A. Beck Depression Inventory Manual 1987, Psychological Corporation, San Antonio,TX.
5. Booij L., Van der Does A.J., Riedel W.J. Monoamine depletion in psychiatric and healthy populations: review. Molecular Psychiatry 2003, 8:951-973.
6. Broadbent D.E., Cooper P.F., FitzGerald P., Parkes K.R. The Cognitive Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology 1982, 21:1-16.
7. Clay T.H., Gualtieri C.T., Evans R.W., Gullion C.M. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacology Bulletin 1988, 24:143-148.
8. Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depression and Anxiety 2005, 21:78-89.
9. Dombrovski A.Y., Butters M.A., Reynolds C.F., Houck P.R., Clark L., Mazumdar S., Szanto K. Cognitive performance in suicidal depressed elderly: preliminary report. American Journal of Geriatric Psychiatry 2008, 16:109-115.
10. Dong J., Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 2001, 155:52-57.
11. Fallon B.A., Keilp J.G., Corbera K.M., Petkova E., Britton C.B., Dwyer E., Slavov I., Cheng J., Dobkin J., Nelson D.R., Sackeim H.A. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008, 70:992-1003.
12. Fava M., Graves L.M., Benazzi F., Scalia M.J., Iosifescu D.V., Alpert J.E., Papakostas G.I. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. Journal of Clinical Psychiatry 2006, 67:1754-1759.
13. Ferguson J.M., Wesnes K.A., Schwartz G.E. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology 2003, 18:9-14.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) Version 2.0 1998, Biometrics Research Department, New York State Psychiatric Institute, New York.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W., Benjamin L. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) Version 2.0 1996, Biometrics Research Department, New York State Psychiatric Institute, New York.
16. Gallassi R., Di Sarro R., Morreale A., Amore M. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. Journal of Affective Disorders 2006, 91:243-250.
17. Grunebaum M.F., Ellis S.P., Duan N., Burke A.K., Oquendo M.A., Mann J.J. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology 2012, 37:697-706.
18. Grunebaum M.F., Keilp J.G., Ellis S.P., Sudol K., Bauer N., Burke A.K., Oquendo M.A., Mann J.J. SSRI versus bupropion effects on symptom clusters in suicidal depression: post-hoc analysis of a randomized clinical trial. Journal of Clinical Psychiatry 2013, 79:872-879.
19. Gualtieri C.T., Johnson L.G. Bupropion normalizes cognitive performance in patients with depression. Medscape General Medicine 2007, 9:22.
20. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960, 23:56-62.
21. Healy E., McKeon P. Dopaminergic sensitivity and prediction of antidepressant response. Journal of Psychopharmacology 2000, 14:152-156.
22. Henriksson M.M., Aro H.M., Marttunen M.J., Heikkinen M.E., Isometsa E.T., Kuoppasalmi K.I., Lonnqvist J.K. Mental disorders and comorbidity in suicide. American Journal of Psychiatry 1993, 150:935-940.
23. Herrera-Guzman I., Gudayol-Ferre E., Herrera-Abarca J.E., Herrera-Guzman D., Montelongo-Pedraza P., Padros Blazquez F., Pero-Cebollero M., Guardia-Olmos J. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. Journal of Affective Disorders 2010, 123:341-350.
24. Herrera-Guzman I., Gudayol-Ferre E., Herrera-Guzman D., Guardia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of Psychiatric Research 2009, 43:855-863.
25. Herrera-Guzman I., Gudayol-Ferre E., Lira-Mandujano J., Herrera-Abarca J., Herrera-Guzman D., Montoya-Perez K., Guardia-Olmos J. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Research 2008, 160:72-82.
26. Jaeger J., Berns S., Uzelac S., Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research 2006, 145:39-48.
27. Jollant F., Lawrence N.L., Olie E., Guillaume S., Courtet P. The suicidal mind and brain: a review of neuropsychological and neuroimaging studies. World Journal of Biological Psychiatry 2011, 12:319-339.
28. Keilp J.G., Gorlyn M., Oquendo M.A., Burke A.K., Mann J.J. Attention deficit in depressed suicide attempters. Psychiatry Research 2008, 159:7-17.
29. Keilp J.G., Gorlyn M., Russell M., Oquendo M.A., Burke A.K., Harkavy-Friedman J., Mann J.J. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychological Medicine 2013, 43:539-551.
30. Keilp J.G., Sackeim H.A., Brodsky B.S., Oquendo M.A., Malone K.M., Mann J.J. Neuropsychological dysfunction in depressed suicide attempters. American Journal of Psychiatry 2001, 158:735-741.
31. Keilp J.G., Sackeim H.A., Mann J.J. Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Research 2005, 135:191-201.
32. King D.A., Conwell Y., Cox C., Henderson R.E., Denning D.G., Caine E.D. A neuropsychological comparison of depressed suicide attempters and nonattempters. Journal of Neuropsychiatry and Clinical Neuroscience 2000, 12:64-70.
33. Majer M., Ising M., Kunzel H., Binder E.B., Holsboer F., Modell S., Zihl J. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychological Medicine 2004, 34:1453-1463.
34. Marzuk P.M., Hartwell N., Leon A.C., Portera L. Executive functioning in depressed patients with suicidal ideation. Acta Psychiatrica Scandinavica 2005, 112:294-301.
35. McNair D.M., Lour M., Droppleman J.F. Manual for the Profile of Mood States 1971, Educational and Industrial Testing Service, San Diego, CA.
36. Murrough J.W., Iacoviello B., Neumeister A., Charney D.S., Iosifescu D.V. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiology of Learning and Memory 2011, 96:553-563.
37. Oquendo M.A., Halberstam B., Mann J.J. Risk factors for suicidal behavior: the utility and limitations of research instruments. Standardized Evaluation in Clinical Practice, Review of Psychiatry 2003, 102-130. American Psychiatric Publishing, Washington, DC. M. First (Ed.).
38. Paelecke-Habermann Y., Pohl J., Leplow B. Attention and executive functions in remitted major depression patients. Journal of Affective Disorders 2005, 89:125-135.
39. Richard-Devantoy S., Berlim M.T., Jollant F. A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders. Psychological Medicine 2014, 44:1663-1673.
40. Richard-Devantoy S., Berlim M.T., Jollant F. Suicidal behaviour and memory: a systematic review and meta-analysis. World Journal of Biological Psychiatry 2014, 12:1-23.
41. Sackeim H.A., Keilp J.G., Rush A.J., George M.S., Marangell L.B., Dormer J.S., Burt T., Lisanby S.H., Husain M., Cullum C.M., Oliver N., Zboyan H. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychology and Behavioral Neurology 2001, 14:53-62.
42. Wechsler D. Wechsler Adult Intelligence Scale 1997, The Psychological Corporation, San Antonio, TX. Third edition.
43. Westheide J., Quednow B.B., Kuhn K.U., Hoppe C., Cooper-Mahkorn D., Hawellek B., Eichler P., Maier W., Wagner M. Executive performance of depressed suicide attempters: the role of suicidal ideation. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:414-421.
44. Wilens T.E., Haight B.R., Horrigan J.P., Hudziak J.J., Rosenthal N.E., Connor D.F., Hampton K.D., Richard N.E., Modell J.G. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biological Psychiatry 2005, 57:793-801.